Detalles de la búsqueda
1.
Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease.
Clin Gastroenterol Hepatol
; 22(1): 144-153.e2, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37391056
2.
Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: UniStar study long-term extension results.
J Pediatr Gastroenterol Nutr
; 2024 May 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38801079
3.
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
Gastroenterology
; 162(6): 1650-1664.e8, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35134323
4.
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med
; 381(13): 1201-1214, 2019 09 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-31553833
5.
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial.
Clin Gastroenterol Hepatol
; 20(3): 578-590.e4, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33618023
6.
Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 18(10): 2244-2255.e9, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31816446
7.
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
N Engl J Med
; 375(20): 1946-1960, 2016 11 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-27959607
8.
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
Gastroenterology
; 154(6): 1660-1671, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29409871
9.
Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.
Clin Gastroenterol Hepatol
; 17(8): 1525-1532.e1, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30267864
10.
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Gastroenterology
; 155(4): 1045-1058, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29909019
11.
Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Rheumatology (Oxford)
; 58(3): 441-446, 2019 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30412238
12.
Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitis.
J Pharmacokinet Pharmacodyn
; 45(6): 803-816, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30377888
13.
Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease.
J Pharmacokinet Pharmacodyn
; 44(5): 425-436, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28623612
14.
Factors associated with short- and long-term outcomes of therapy for Crohn's disease.
Clin Gastroenterol Hepatol
; 13(3): 539-547.e2, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25245629
15.
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Gastroenterology
; 146(1): 96-109.e1, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23770005
16.
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Gastroenterology
; 146(1): 85-95; quiz e14-5, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23735746
17.
Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
Gastroenterology
; 147(6): 1296-1307.e5, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25173754
18.
Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease.
Clin Ther
; 44(10): 1336-1355, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36150926
19.
Population Pharmacokinetic and Exposure-Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid Arthritis.
Clin Ther
; 44(3): 457-464.e2, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35183373
20.
Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn's Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study.
J Crohns Colitis
; 15(11): 1931-1942, 2021 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34037715